Clozapine prescription rates in Southeast Europe: A cross-sectional study

Abstract

IntroductionInternational reports indicate that clozapine is under prescribed. Yet, this has not been explored in Southeast European (SEE) countries. This cross-sectional study investigates clozapine prescription rates in a sample of 401 outpatients with psychosis from Bosnia and Herzegovina, Kosovo by United Nations resolution, North Macedonia, Montenegro and Serbia.MethodsDescriptive analysis was used to explore clozapine prescription rates; daily antipsychotic dosage was calculated and converted into olanzapine equivalents. Patients receiving clozapine were compared to those not receiving clozapine; next those that were on clozapine monotherapy were compared to those who were on clozapine polytherapy regime.ResultsIt was showed that clozapine was prescribed to 37.7% of patients (with cross-country variation: from 25% in North Macedonia to 43.8% in Montenegro), with average dose of 130.7 mg/daily. The majority of patients on clozapine (70.5%) were prescribed at least one more antipsychotic (the most frequent combination was with haloperidol).DiscussionOur findings suggested that clozapine prescription rate in SEE outpatients is higher than in Western Europe. The average dose is significantly below the optimal therapeutic dosage recommended by clinical guidelines, and clozapine polytherapy is common. This might indicate that clozapine is prescribed mainly for its sedative effect rather than antipsychotic. We hope that this finding will be taken up by relevant stakeholders to address this non-evidence-based practice.

Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia

“…Although clozapine is clinically indicated for approximately 30% of patients with TRS, prescription rates were lower than expected for high-income countries and the use of nontherapeutic doses ( 36 , 37 ). In our study, clozapine was only prescribed to 4.5% of participants, whereas Massuda et al.…”

Clinical and pharmacological factors influencing serum clozapine and norclozapine levels

“…Although CLO is mainly used in monotherapy, it is sometimes also used in combination with other drugs. In this year’s cross-sectional South-Eastern European study 70.5% of patients received CLO in polytherapy ( Russo et al, 2023 ). The findings of our study suggest that, based on the pharmacokinetic and pharmacodynamic properties and the potential interactions of CLO, the use of one or two additional psychotropic drugs does not have to be associated with a high risk of toxicity.…”